让患者用得起、用得上（专家点评）

Core Viewpoint - The rapid development of innovative drugs in China has led to a market size exceeding 100 billion yuan, with a notable surge in biopharmaceuticals compared to traditional small molecule drugs [1] Industry Development - The transition from generic drugs to innovative drugs in China's pharmaceutical industry has been supported by policy reforms since 2015, addressing issues like review backlog and delayed market entry for innovative drugs [1] - The State Council's implementation plan approved in July last year aims to provide comprehensive policy support for innovative drug development, optimizing review processes and healthcare institution assessments [1] Investment and Accessibility - Significant investment is required for innovative drug research and development, with a focus on ensuring affordability and accessibility for patients [1] - Since 2018, 149 innovative drugs, primarily first-class innovative drugs, have been included in the medical insurance catalog, reducing the financial burden on patients [1] Collaborations and Market Confidence - Recent collaborations between multinational and domestic pharmaceutical companies regarding high-quality innovative drugs have involved substantial financial agreements, enhancing confidence in the development of China's innovative drug industry [1]